The FDA has ushered in a new era in lower cost cancer meds with its approval of Amgen’s Mvasi, a biosimilar of Roche’s blockbuster drug Avastin.
A new study in JAMA has put the focus back on the price of Mallinckrodt's controversial med, H.P. Acthar gel.
Teva Pharmaceutical offered Lundbeck CEO Kåre Schultz a pay package worth up to $52 million to join as its leader.
Following a sales fraud investigation that led to major executive changes, Alexion’s new management is rolling out its first corporate revamp.
Dupixent, the Sanofi and Regeneron drug on a blockbuster arc in atopic dermatitis, has returned significant results in patients with severe asthma.
Analysts think Regeneron and Sanofi’s injected immunology drug Dupixent could face some tough competition from easier-to-take JAK inhibitors.
The outlook brightened today for Bristol-Myers Squibb’s Opdivo-Yervoy combo with new results in a trial as a first-line treatment in kidney cancer.
Novo Nordisk has settled, for nearly $60 million, a batch of lawsuits over past marketing of its Type 2 diabetes drug Victoza.
Kite Pharma's ability to handle the complex manufacturing of its CAR-T cancer treatment is one reason Gilead is paying $11.9 billion for the company.
Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.